## Richard C Dart

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/473720/publications.pdf

Version: 2024-02-01

		76326	6	6911
127	6,497	40		78
papers	citations	h-index		g-index
130	130	130		5065
all docs	docs citations	times ranked		citing authors

#	Article	IF	CITATIONS
1	Trends in Opioid Analgesic Abuse and Mortality in the United States. New England Journal of Medicine, 2015, 372, 241-248.	27.0	1,002
2	Bites of Venomous Snakes. New England Journal of Medicine, 2002, 347, 347-356.	27.0	398
3	2011 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 29th Annual Report. Clinical Toxicology, 2012, 50, 911-1164.	1.9	354
4	Efficacy, safety, and use of snake antivenoms in the United States. Annals of Emergency Medicine, 2001, 37, 181-188.	0.6	232
5	A Randomized Multicenter Trial of Crotalinae Polyvalent Immune Fab (Ovine) Antivenom for the Treatment for Crotaline Snakebite in the United States. Archives of Internal Medicine, 2001, 161, 2030.	3.8	196
6	Classification and definition of misuse, abuse, and related events in clinical trials: ACTTION systematic review and recommendations. Pain, 2013, 154, 2287-2296.	4.2	187
7	Unified treatment algorithm for the management of crotaline snakebite in the United States: results of an evidence-informed consensus workshop. BMC Emergency Medicine, 2011, 11, 2.	1.9	167
8	Trends in abuse and misuse of prescription opioids among older adults. Drug and Alcohol Dependence, 2015, 149, 117-121.	3.2	144
9	Validation of a Severity Score for the Assessment of Crotalid Snakebite. Annals of Emergency Medicine, 1996, 27, 321-326.	0.6	143
10	Acetaminophen Poisoning: an Evidence-Based Consensus Guideline for Out-of-Hospital Management. Clinical Toxicology, 2006, 44, 1-18.	1.9	143
11	Affinity-Purified, Mixed Monospecific Crotalid Antivenom Ovine Fab for the Treatment of Crotalid Venom Poisoning. Annals of Emergency Medicine, 1997, 30, 33-39.	0.6	140
12	Tampering with Prescription Opioids: Nature and Extent of the Problem, Health Consequences, and Solutions. American Journal of Drug and Alcohol Abuse, 2011, 37, 205-217.	2.1	137
13	Does Therapeutic Use of Acetaminophen Cause Acute Liver Failure?. Pharmacotherapy, 2007, 27, 1219-1230.	2.6	123
14	Effect of Maximal Daily Doses of Acetaminophen on the Liver of Alcoholic Patients. Archives of Internal Medicine, 2001, 161, 2247.	3.8	115
15	The Underrecognized Toll of Prescription Opioid Abuse on Young Children. Annals of Emergency Medicine, 2009, 53, 419-424.	0.6	110
16	North American snake envenomation: diagnosis, treatment, and management. Emergency Medicine Clinics of North America, 2004, 22, 423-443.	1.2	105
17	Expert Consensus Guidelines for Stocking of Antidotes in Hospitals That Provide Emergency Care. Annals of Emergency Medicine, 2009, 54, 386-394.e1.	0.6	101
18	Pediatric Fatalities Associated With Over the Counter (Nonprescription) Cough and Cold Medications. Annals of Emergency Medicine, 2009, 53, 411-417.	0.6	98

#	Article	IF	Citations
19	Reduced Abuse, Therapeutic Errors, and Diversion Following Reformulation of Extended-Release Oxycodone in 2010. Journal of Pain, 2013, 14, 1122-1130.	1.4	93
20	Abuse and diversion of buprenorphine sublingual tablets and film. Journal of Substance Abuse Treatment, 2014, 47, 27-34.	2.8	84
21	Prevalence and description of kratom ( <i>Mitragyna speciosa</i> ) use in the United States: a crossâ€sectional study. Addiction, 2021, 116, 176-181.	3.3	81
22	Combined evidence-based literature analysis and consensus guidelines for stocking of emergency antidotes in the United States. Annals of Emergency Medicine, 2000, 36, 126-132.	0.6	80
23	Insufficient Stocking of Poisoning Antidotes in Hospital Pharmacies. JAMA - Journal of the American Medical Association, 1996, 276, 1508.	7.4	78
24	Post-marketing Surveillance of Methadone and Buprenorphine in the United States. Pain Medicine, 2010, 11, 1078-1091.	1.9	75
25	Intravenous Acetaminophen in the United States: latrogenic Dosing Errors. Pediatrics, 2012, 129, 349-353.	2.1	74
26	Resolution of compartment syndrome after rattlesnake envenomation utilizing non-invasive measures. Journal of Emergency Medicine, 2003, 24, 285-288.	0.7	66
27	Crowdsourcing Black Market Prices For Prescription Opioids. Journal of Medical Internet Research, 2013, 15, e178.	4.3	66
28	Monitoring risk: Post marketing surveillance and signal detection. Drug and Alcohol Dependence, 2009, 105, S26-S32.	3.2	62
29	The effect of an abuseâ€deterrent opioid formulation (OxyContin) on opioid abuseâ€related outcomes in the postmarketing setting. Clinical Pharmacology and Therapeutics, 2016, 100, 275-286.	4.7	57
30	Relationship of Venom Effects to Venom Antigen and Antivenom Serum Concentrations in a Patient With Crotalus atrox Envenomation Treated With a Fab Antivenom. Annals of Emergency Medicine, 1997, 30, 49-53.	0.6	54
31	Root Causes, Clinical Effects, and Outcomes of Unintentional Exposures to Buprenorphine by Young Children. Journal of Pediatrics, 2013, 163, 1377-1383.e3.	1.8	51
32	Comparative Rates of Mortality and Serious Adverse Effects Among Commonly Prescribed Opioid Analgesics. Drug Safety, 2018, 41, 787-795.	3.2	49
33	Short-Term Outcomes After Fab Antivenom Therapy for Severe Crotaline Snakebite. Annals of Emergency Medicine, 2011, 57, 128-137.e3.	0.6	48
34	Neutralization of Latrodectus mactansand L. hesperus Venom by Redback Spider (L. hasseltii) Antivenom. Journal of Toxicology: Clinical Toxicology, 2001, 39, 119-123.	1.5	47
35	Poisoning in the United States: 2012 Emergency Medicine Report of the National Poison Data System. Annals of Emergency Medicine, 2015, 65, 416-422.	0.6	47
36	Expert Consensus Guidelines for Stocking of Antidotes in Hospitals That Provide Emergency Care. Annals of Emergency Medicine, 2018, 71, 314-325.e1.	0.6	47

#	Article	IF	Citations
37	Rethinking the Toxic Methanol Level. Journal of Toxicology: Clinical Toxicology, 2003, 41, 793-800.	1.5	46
38	Assessment of the abuse of tapentadol immediate release: The first 24 months. Journal of Opioid Management, 2012, 8, 395-402.	0.5	45
39	Sustained reduction of diversion and abuse after introduction of an abuse deterrent formulation of extended release oxycodone. Drug and Alcohol Dependence, 2016, 168, 219-229.	3.2	44
40	Prescription opioid exposures and adverse outcomes among older adults. Pharmacoepidemiology and Drug Safety, 2016, 25, 539-544.	1.9	43
41	Surgical Considerations in the Management of Pit Viper Snake Envenomation. Journal of the American College of Surgeons, 2013, 217, 726-735.	0.5	41
42	Law enforcementâ€derived data on gabapentin diversion and misuse, 2002â€2015: diversion rates and qualitative research findings. Pharmacoepidemiology and Drug Safety, 2017, 26, 1083-1086.	1.9	41
43	Kratom (Mitragyna Speciosa) Liver Injury: A Comprehensive Review. Drugs, 2020, 80, 263-283.	10.9	41
44	Medical outcomes associated with prescription opioid abuse via oral and non-oral routes of administration. Drug and Alcohol Dependence, 2017, 175, 140-145.	3.2	39
45	Assessment of Tapentadol API Abuse Liability With the Researched Abuse, Diversion and Addiction-Related Surveillance System. Journal of Pain, 2018, 19, 439-453.	1.4	39
46	Toxicity From Repeated Doses of Acetaminophen in Children. American Journal of Therapeutics, 2014, 21, 174-183.	0.9	36
47	A randomized, placebo-controlled trial to determine the course of aminotransferase elevation during prolonged acetaminophen administration. BMC Pharmacology & Expression (2014), 15, 39.	2.4	36
48	Effects of constriction bands on rattlesnake venom absorption: A pharmacokinetic study. Annals of Emergency Medicine, 1992, 21, 1086-1093.	0.6	35
49	Abuse and Diversion of Immediate Release Opioid Analgesics as Compared to Extended Release Formulations in the United States. PLoS ONE, 2016, 11, e0167499.	2.5	35
50	Medically Significant Late Bleeding After Treated Crotaline Envenomation: A Systematic Review. Annals of Emergency Medicine, 2014, 63, 71-78.e1.	0.6	34
51	Paracetamol (acetaminophen) protein adduct concentrations during therapeutic dosing. British Journal of Clinical Pharmacology, 2016, 81, 562-568.	2.4	34
52	Quantification of a biomarker of acetaminophen protein adducts in human serum by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry: Clinical and animal model applications. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2015, 985, 131-141.	2.3	33
53	Using poison center exposure calls to predict prescription opioid abuse and misuseâ€related emergency department visits. Pharmacoepidemiology and Drug Safety, 2014, 23, 18-25.	1.9	32
54	Ovine Desipramine Antibody Fragments Reverse Desipramine Cardiovascular Toxicity in the Rat. Annals of Emergency Medicine, 1996, 27, 309-315.	0.6	30

#	Article	IF	CITATIONS
55	Safety Profile of Cough and Cold Medication Use in Pediatrics. Pediatrics, 2017, 139, .	2.1	30
56	A Randomized, Double-Blind, Placebo-Controlled Trial of a Highly Purified Equine F(ab)2 Antibody Black Widow Spider Antivenom. Annals of Emergency Medicine, 2013, 61, 458-467.	0.6	28
57	Recurrent Coagulopathy After Antivenom Treatment of Crotalid Snakebite. Southern Medical Journal, 2000, 93, 562-566.	0.7	27
58	Time to reconstitution: purified Fab antivenom vs. unpurified IgG antivenom. Toxicon, 2001, 39, 729-731.	1.6	27
59	Effect of Therapeutic Doses of Acetaminophen (up to 4 g/day) on Serum Alanine Aminotransferase Levels in Subjects Consuming Ethanol: Systematic Review and Metaâ€analysis of Randomized Controlled Trials. Pharmacotherapy, 2012, 32, 784-791.	2.6	27
60	A Preliminary Study of Tricyclic Antidepressant (TCA) Ovine FAB for TCA Toxicity. Clinical Toxicology, 2006, 44, 275-281.	1.9	26
61	Diversion and Illicit Sale of Extended Release Tapentadol in the United States. Pain Medicine, 2016, 17, 1490-1496.	1.9	26
62	Risk management and post-marketing surveillance for the abuse of medications acting on the central nervous system: Expert Panel Report. Drug and Alcohol Dependence, 2009, 105, S65-S71.	3.2	25
63	Treatment of amitriptyline poisoning with ovine antibody to tricyclic antidepressants. Lancet, The, 1999, 354, 1614-1615.	13.7	22
64	Inhalational abuse of methanol products: elevated methanol and formate levels without vision loss. American Journal of Emergency Medicine, 2006, 24, 725-728.	1.6	22
65	Consistency Between Opioid-Related Mortality Trends Derived From Poison Center and National Vital Statistics System, United States, 2006–2016. American Journal of Public Health, 2018, 108, 1639-1645.	2.7	22
66	An Online Survey for Pharmacoepidemiological Investigation (Survey of Non-Medical Use of) Tj ETQq0 0 0 rgBT	/Overlock	10 Tf 50 302 <sup>-</sup>
67	Tricyclic Antidepressants Directly Depress Human Myocardial Mechanical Function Independent of Effects on the Conduction System. Academic Emergency Medicine, 2001, 8, 1122-1127.	1.8	19
68	Nonmedical Use of Tapentadol Immediate Release by College Students. Clinical Journal of Pain, 2014, 30, 685-692.	1.9	19
69	Do abuse deterrent opioid formulations work?. Journal of Opioid Management, 2017, 13, 365-378.	0.5	16
70	Tramadol non-medical use in Four European countries: A comparative analysis. Drug and Alcohol Dependence, 2020, 217, 108367.	3.2	15
71	Prescription opioid treatment for non-cancer pain and initiation of injection drug use: large retrospective cohort study. BMJ, The, 2021, 375, e066965.	6.0	15
72	Effectiveness of Delayed Use of Crotalidae Polyvalent Immune Fab (Ovine) Antivenom. Journal of Toxicology: Clinical Toxicology, 2004, 42, 321-324.	1.5	14

#	Article	IF	CITATIONS
73	Analysis of the Abuse and Diversion of the Buprenorphine Transdermal Delivery System. Journal of Pain, 2016, 17, 745-752.	1.4	14
74	Unit-Dose Packaging and Unintentional Buprenorphine-Naloxone Exposures. Pediatrics, 2018, 141, e20174232.	2.1	14
75	Nonmedical use of benzodiazepines and Zâ€drugs in the UK. British Journal of Clinical Pharmacology, 2021, 87, 1676-1683.	2.4	14
76	Measuring prescription opioid misuse and its consequences. British Journal of Clinical Pharmacology, 2021, 87, 1647-1653.	2.4	14
77	Understanding abuse of buprenorphine/naloxone film versus tablet products using data from ASI-MV® substance use disorder treatment centers and RADARS® System Poison Centers. Journal of Substance Abuse Treatment, 2018, 84, 42-49.	2.8	13
78	Opioid discontinuation as an institutional mandate: Questions and answers on why we wrote to the Centers for Disease Control and Prevention. Substance Abuse, 2019, 40, 466-468.	2.3	13
79	Adverse events associated with diphenhydramine in children, 2008–2015. Clinical Toxicology, 2020, 58, 99-106.	1.9	13
80	Seasonal variation in suicidal behavior with prescription opioid medication. Journal of Affective Disorders, 2014, 158, 30-36.	4.1	11
81	The Efficacy of Antivenin Latrodectus (Black Widow) Equine Immune $F(ab\hat{E}^1)$ 2 Versus Placebo in the Treatment of Latrodectism: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial. Annals of Emergency Medicine, 2019, 74, 439-449.	0.6	11
82	Scoring the best deal: Quantity discounts and street price variation of diverted oxycodone and oxymorphone. Pharmacoepidemiology and Drug Safety, 2019, 28, 25-30.	1.9	11
83	Pediatric Fatalities Associated With Over-the-Counter Cough and Cold Medications. Pediatrics, 2021, 148, .	2.1	11
84	Medication Errors From Over-the-Counter Cough and Cold Medications in Children. Academic Pediatrics, 2020, 20, 327-332.	2.0	10
85	Non-medical Use of Prescription Gabapentinoids (Gabapentin and Pregabalin) in Five European Countries. Frontiers in Psychiatry, 2021, 12, 676224.	2.6	10
86	Efficacy of delayed administration of crotalid antivenom and crystalloid fluids. Toxicon, 1988, 26, 1218-1221.	1.6	9
87	Heat and motion stability of polyvalent Crotalidae antivenin, ovine Fab. Toxicon, 1998, 36, 377-382.	1.6	9
88	Attenuation of Verapamil-induced Myocardial Toxicity in an Ex-vivo Rat Model Using a Verapamil-specific Ovine Immunoglobin. Academic Emergency Medicine, 2001, 8, 950-955.	1.8	8
89	The Safety Profile of Sustained Release Paracetamol During Therapeutic Use and Following Overdose. Drug Safety, 2005, 28, 1045-1056.	3.2	8
90	Changes in misuse and abuse of prescription opioids following implementation of Extendedâ€Release and Longâ€Acting Opioid Analgesic Risk Evaluation and Mitigation Strategy. Pharmacoepidemiology and Drug Safety, 2017, 26, 1061-1070.	1.9	8

#	Article	IF	Citations
91	Nonmedical use of alprazolam in the UK: Results from a nationally representative survey. British Journal of Clinical Pharmacology, 2019, 85, 1841-1845.	2.4	8
92	The impact of the prescription opioid epidemic on young children: Trends and mortality. Drug and Alcohol Dependence, 2020, 211, 107924.	3.2	8
93	Online Conversation Monitoring to Understand the Opioid Epidemic: Epidemiological Surveillance Study. JMIR Public Health and Surveillance, 2020, 6, e17073.	2.6	8
94	Evaluation of the quality and value of data sources for postmarket surveillance of the safety of cough and cold medications in children. BMC Medical Research Methodology, 2018, 18, 175.	3.1	7
95	Opioid discontinuation as an institutional mandate: Questions and answers on why we wrote to the Centers for Disease Control and Prevention. Substance Abuse, 2019, 40, 4-6.	2.3	7
96	Brief Report: Characterization of Marijuana Use in US College Students by State Marijuana Legalization Status as Reported to an Online Survey. American Journal on Addictions, 2019, 28, 266-269.	1.4	7
97	Postmarketing Analysis of Misuse, Abuse, and Diversion of Xtampza ER. Pain Medicine, 2020, 21, 3660-3668.	1.9	7
98	Nonâ€medical use of benzodiazepines and GABA analogues in Europe. British Journal of Clinical Pharmacology, 2021, 87, 1684-1694.	2.4	7
99	The prescription paradox of acetaminophen safety. Pharmacoepidemiology and Drug Safety, 2016, 25, 599-601.	1.9	6
100	Measures That Identify Prescription Medication Misuse, Abuse, and Related Events in Clinical Trials: ACTTION Critique and Recommended Considerations. Journal of Pain, 2017, 18, 1287-1294.	1.4	6
101	Transition to two-bag intravenous acetylcysteine for acetaminophen overdose: a poison center's experience. Clinical Toxicology, 2019, 57, 217-218.	1.9	6
102	Understanding multiâ€pill ingestion of prescription opioids: Prevalence, characteristics, and motivation. Pharmacoepidemiology and Drug Safety, 2019, 28, 117-121.	1.9	6
103	Drug product dispensing and estimates of use in a general population survey as a signal detection problem. Pharmacoepidemiology and Drug Safety, 2021, 30, 1132-1139.	1.9	6
104	Web-Based Discussion and Illicit Street Sales of Tapentadol and Oxycodone in Australia: Epidemiological Surveillance Study. JMIR Public Health and Surveillance, 2021, 7, e29187.	2.6	6
105	Accidental paracetamol overdosing and fulminant hepatic failure in children. Medical Journal of Australia, 2000, 173, 558-559.	1.7	5
106	The Genomics of Elevated ALT and Adducts in Therapeutic Acetaminophen Treatment: a Pilot Study. Journal of Medical Toxicology, 2021, 17, 160-167.	1.5	5
107	Cohort profile: development and characteristics of a retrospective cohort of individuals dispensed prescription opioids for non-cancer pain in British Columbia, Canada. BMJ Open, 2021, 11, e043586.	1.9	5
108	Metabolomic markers predictive of hepatic adaptation to therapeutic dosing of acetaminophen. Clinical Toxicology, 2022, 60, 221-230.	1.9	5

#	Article	IF	CITATIONS
109	The association between the availability of over the counter codeine and the prevalence of non-medical use. European Journal of Clinical Pharmacology, 2022, 78, 1011-1018.	1.9	5
110	An Examination of Serial Urinalyses in Patients with North American Crotalid Envenomation. Journal of Toxicology: Clinical Toxicology, 1998, 36, 329-335.	1.5	4
111	Changes in Mortality Involving Extended-Release and Long-Acting Opioids After Implementation of a Risk Evaluation and Mitigation Strategy. Pain Medicine, 2020, 21, 92-100.	1.9	4
112	An evaluation of online discussion relating to nonmedical use of prescription opioids within the UK. British Journal of Clinical Pharmacology, 2021, 87, 1637-1646.	2.4	4
113	Kratom use in the United States: Response to Grundmann <i>et al</i> Addiction, 2021, 116, 203-204.	3.3	3
114	Trends in adverse events and related health-care facility utilization from cough and cold medication exposures in children. Clinical Toxicology, 2021, 59, 351-354.	1.9	3
115	The Roles of Antidotes in Emergency Situations. Emergency Medicine Clinics of North America, 2022, 40, 381-394.	1.2	3
116	Envenomations by Widow, Recluse, and Medically Implicated Spiders. Toxinology, 2018, , 379-412.	0.2	2
117	Causal inference for evaluating prescription opioid abuse using trendâ€nâ€trend design. Pharmacoepidemiology and Drug Safety, 2019, 28, 716-725.	1.9	2
118	Control of venom-induced tissue injury in copperhead snakebite patients: a post hoc sub-group analysis of a clinical trial comparing F(ab') <sub>2</sub> to Fab antivenom. Clinical Toxicology, 2022, 60, 521-523.	1.9	2
119	Adverse Events Related to Accidental Unintentional Ingestions From Cough and Cold Medications in Children. Pediatric Emergency Care, 2022, 38, e100-e104.	0.9	2
120	Comparison of hospital claims and poison center data to evaluate health impact of opioids, cannabis and synthetic cannabinoids. American Journal of Emergency Medicine, 2022, 53, 150-153.	1.6	2
121	Clustering patterns in polysubstance mortality in the United States in 2017: a multiple correspondence analysis of death certificate data. Annals of Epidemiology, 2023, 77, 119-126.	1.9	2
122	Abuse-Deterrent Formulations of Prescription Opioids. JAMA Psychiatry, 2015, 72, 849.	11.0	1
123	Commentary on Mintz et al. (2019): Unintended or intended? Coming to grips with the opioid crisis. Addiction, 2019, 114, 2160-2161.	3.3	1
124	Impact of product safety changes on accidental exposures to liquid laundry packets in children. Clinical Toxicology, 2021, 59, 392-399.	1.9	1
125	Insights and issues from FDA Advisory Committee meetings on abuse-deterrent opioids. Journal of Opioid Management, 2017, 13, 379-389.	0.5	1
126	Association Between Prescription Opioid Therapy for Noncancer Pain and Hepatitis C Virus Seroconversion. JAMA Network Open, 2022, 5, e2143050.	5.9	1

#	Article	IF	CITATIONS
127	Envenomations by Widow, Recluse, and Medically Implicated Spiders. Toxinology, 2017, , 1-26.	0.2	0